ORIGINAL RESEARCH article
Front. Cell Dev. Biol., 15 June 2021
Sec. Molecular and Cellular Pathology
Volume 9 - 2021 | https://doi.org/10.3389/fcell.2021.661461
RETRACTED: miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease
Sara R. Oliveira 1
Pedro A. Dionísio 1
Maria M. Gaspar 1
Leonor Correia Guedes 2,3
Miguel Coelho 2,3
Mário M. Rosa 2,3,4
Joaquim J. Ferreira 2,4
Joana D. Amaral 1
Cecília M. P. Rodrigues 1*
1. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
2. Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
3. Department of Neuroscience and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
4. Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Summary
Citation
Oliveira SR, Dionísio PA, Gaspar MM, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ, Amaral JD and Rodrigues CMP (2021) RETRACTED: miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease. Front. Cell Dev. Biol. 9:661461. doi: 10.3389/fcell.2021.661461
Received
30 January 2021
Accepted
19 May 2021
Published
15 June 2021
Volume
9 - 2021
Edited by
Diego Franco, University of Jaén, Spain
Reviewed by
Isabella Russo, University of Turin, Italy; Yehong Du, Chongqing Medical University, China; Wanli Smith, Johns Hopkins University, United States
Updates
This article was submitted to Molecular Medicine, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.